Key result
Oral anticoagulant treatment in elderly patients with atrial fibrillation was associated with a lower risk of stroke or systemic embolism compared to no treatment.
Why the study?
While oral anticoagulants mitigate stroke risk in AF, clinical and economic outcomes needed comparison between OAC-treated and untreated elderly AF patients.
Does oral anticoagulant therapy reduce stroke/systemic embolism and mortality in elderly patients with atrial fibrillation compared to no treatment?
Cohort (n=1,421,187)
Does oral anticoagulant therapy reduce stroke/systemic embolism and mortality in elderly patients with atrial fibrillation compared to no treatment?
In a real-world elderly Medicare population, oral anticoagulant treatment for atrial fibrillation was associated with reduced stroke and mortality, and lower total healthcare costs, despite an increased risk of major bleeding.
Answers are grounded in this paper and cite their sources.
OAC use may improve outcomes in elderly AF; leaves open causal confirmation and cost-effectiveness via RCTs.
BACKGROUND: Oral anticoagulants (OACs) mitigate the risk of stroke in atrial fibrillation (AF) patients. OBJECTIVE: Elderly AF patients who were treated with OACs (apixaban, dabigatran, edoxaban, rivaroxaban, or warfarin) were compared against AF patients who were not treated with OACs with respect to their clinical and economic outcomes. METHODS: Newly diagnosed AF patients were identified between January 2013 and December 2017 in the Medicare database. Evidence of an OAC treatment claim on or after the first AF diagnosis was used to classify patients into treatment-defined cohorts, and these cohorts were further stratified based on the initial OAC prescribed. The risks of stroke/systemic embolism (SE), major bleeding (MB), and death were analyzed using inverse probability treatment weighted time-dependent Cox regression models, and costs were compared with marginal structural models. RESULTS: The two treatment groups were composed of 1,421,187 AF patients: OAC treated (N = 583,350, 41.0% [36.4% apixaban, 4.9% dabigatran, 0.1% edoxaban, 26.7% rivaroxaban, and 31.9% warfarin patients]) and untreated (N = 837,837, 59.0%). OAC-treated patients had a lower adjusted risk of stroke/SE compared to untreated patients (hazard ratio [HR]: 0.70; 95% confidence interval [CI]: 0.68-0.72). Additionally patients receiving OACs had a lower adjusted risk of death (HR: 0.56; 95% CI: 0.55-0.56) and a higher risk of MB (HR: 1.57; 95% CI: 1.54-1.59) and this trend was consistent across each OAC sub-group. The OAC-treated cohort had lower adjusted total healthcare costs per patient per month ($4,381 vs $7,172; p < .0001). CONCLUSION: For the OAC-treated cohort in this elderly US population, stroke/SE and all-cause death were lower, while risk of MB was higher. Among OAC treated patients, total healthcare costs were lower than those of the untreated cohort.
No takes yet. Share an insight, caveat, or question.
Munir et al. (2022) conducted a cohort in Atrial fibrillation (n=1,421,187). Oral anticoagulants vs. No oral anticoagulant treatment was evaluated on Stroke/systemic embolism (SE) (HR 0.70, 95% CI 0.68-0.72). Oral anticoagulant treatment in elderly patients with atrial fibrillation was associated with a lower risk of stroke or systemic embolism compared to no treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: